Once and twice a week transdermal estradiol delivery systems: clinical efficacy and plasma estrogen levels

We compared the clinical efficacy and circulating estrogen levels from two transdermal delivery systems, 'drug-in-adhesive' type, in 20 healthy postmenopausal women. Both patches, developed by Beta Pharmaceutical Laboratories in Argentina, deliver estradiol at a rate of 50 fig/day; the rep...

Full description

Saved in:
Bibliographic Details
Published in:Climacteric : the journal of the International Menopause Society 1998, Vol.1 (3), p.196-201
Main Authors: Siseles, N. O., Benencia, H., Mesch, V., Gutierrez, P., Novelli, J. A.
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Clinical Efficacy
Estradiol - administration & dosage
Estradiol - blood
Estrogen Replacement Therapy
Estrogen Variation
Estrone - blood
Female
Hormone Replacement Therapy
Humans
Medroxyprogesterone Acetate - administration & dosage
Middle Aged
Postmenopausal
Postmenopause
Protein Binding
Sex Hormone-Binding Globulin - metabolism
Transdermal Administration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We compared the clinical efficacy and circulating estrogen levels from two transdermal delivery systems, 'drug-in-adhesive' type, in 20 healthy postmenopausal women. Both patches, developed by Beta Pharmaceutical Laboratories in Argentina, deliver estradiol at a rate of 50 fig/day; the replacement frequency of system A (TrialSat®) was twice a week and for system B (TrialSat LA®) once a week. The women were treated for 180 days, in a continuous regimen, with additional oral medroxyprogesterone acetate 5 mg/ day for 14 days of each cycle. Blood samples were taken at the end of the wearing period: the 3rd day for Group A and the 7th day for Group B, to determine levels of estradiol, estrone, non-sex hormone binding globulin (SHBG)-bound estradiol and SHBG. Both treatments had similar clinical efficacy and were well tolerated. Plasma estradiol levels were higher in Group A throughout the study, probably owing to the different sampling times. SHBG and non-SHBG-bound estradiol were unchanged in both groups. As there was a similar performance of both delivery systems, the 7-day patch may be preferable, and produce greater compliance.
ISSN:1369-7137
1473-0804
DOI:10.3109/13697139809085541